Navigation Links
Switching drugs regularly improves HIV treatment

NEW YORK (Reuters Health) - When HIV-infected patients alternated their drug regimen every three months, their virus levels stayed down longer than when one regimen was administered continuously.
That news comes from the SWATCH (SWitching Antiviral Therapy Combination against HIV-1) study. Dr. Javier Martinez-Picado, of Hospital Germans Trias I Pujol in Badalona, Spain, and others examined this alternating strategy among HIV patients who //were randomized to one of three regimens.
Regimen A consisted of continuous treatment with didanosine, stavudine, and efavirenz. For regimen B, patients were administered zidovudine, lamivudine and nelfinavir. In regimen C, the patients alternated between the other two regimens every 3 months. The results are reported in the Annals of Internal Medicine .
Response to treatment was similar in patients receiving regimen A or regimen B, so the researchers pooled these two groups when evaluating the results.
The rate of virologic failure - that is, a rise in the amount of virus in the blood above a defined level - was 3.5 higher during the following year in the pooled group than in the alternating therapy group.
Dr. Martinez-Picado's group concludes, "Proactive switching and alternation of antiretroviral regimens with drugs that have different resistance profiles might extend the overall long-term effectiveness of first- and second-line treatment options."
In an editorial, Dr. Michael Saag, of the University of Alabama at Birmingham, points out that current drug regimens are more efficacious than the ones used in the SWATCH study.
However, he agrees with Dr. Martinez-Picado's group that further study of proactive switching seems warranted, but that the strategy should not be routine at this time..


'"/>




Page: 1

Related medicine news :

1. Switching Off Protein Could Play Key Role In Success Of Radiation Therapy For Cancer
2. Switching Genes to Overdrive Improves Muscular Dystrophy Symptoms in Mice
3. Cancer drugs in development nearly doubled since 1995
4. Cipla holds talks with mining giant to supply AIDS drugs for South African workers
5. African HIV strains more resistant to anti HIV drugs
6. Right drugs drastically cut stroke risk
7. Relating heart protection and antihypertensive drugs
8. Enzyme may be target for obesity drugs
9. New HIV cases resist drugs
10. Relief to pregnant women using fertility drugs
11. AIDS drugs linked to heart attack risk
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/28/2017)... Philadelphia, PA (PRWEB) , ... June 28, 2017 ... ... will host a one-day corporate governance program for mid-market executives as a kick-off ... will be held Sunday, Sept. 24, 2017 on the University of Pennsylvania campus, ...
(Date:6/28/2017)... Vancouver, British Columbia (PRWEB) , ... June 28, ... ... (OTCQB: CNZCF) (FSE: ZEON) is pleased to announce that a two year study ... using the Company's Bromley Creek zeolite was successful in remediating potash brine-impacted groundwater. ...
(Date:6/28/2017)... ... June 28, 2017 , ... Designers ... to communities in northern Virginia and DC, is announcing a cooperative charity event ... with Alzheimer’s and other disorders that lead to memory impairment. , The Insight ...
(Date:6/27/2017)... Rolling Meadows, IL (PRWEB) , ... June 27, ... ... they are considering a cosmetic treatment, according to survey data released today by ... Consumer Survey on Cosmetic Dermatologic Procedures indicates the percentage of consumers considering ...
(Date:6/27/2017)... ... 2017 , ... Salucro, the cloud-based payment platform that has ... and provider groups, has announced that it will now offer Parasail’s payment plans ... San Francisco health-finance startup that has launched a series of tech-based products that ...
Breaking Medicine News(10 mins):
(Date:6/14/2017)... , June 14, 2017 The Bio Supply ... City of Fremont and the Biomedical ... bio-pharma industry in California by ... executive networking, and fostering workforce development. The primary focus ... growth of start-ups, as well as small and mid-sized ...
(Date:6/11/2017)... 2017  Eli Lilly and Company (NYSE: LLY ... studies of galcanezumab, an investigational treatment for the prevention ... several key secondary endpoints for galcanezumab compared to placebo ... (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented today at ... Boston . "The ...
(Date:6/8/2017)... , June 8, 2017  Less than a ... hit more than 200,000 companies, including hospital networks, in ... heralded as one of the largest online extortion attempts ... the healthcare market, it is imperative that providers understand ... their data from this — and many other very ...
Breaking Medicine Technology: